The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Editas Medicine Inc shares valued at $19,110 were purchased by O’Neill Gilmore Neil on Sep 03 ’25. At $2.73 per share, O’Neill Gilmore Neil acquired 7,000 shares.
Also, Burkly Linda purchased 800 shares, netting a total of over 2,184 in proceeds.
Before that, Parison Amy had sold 679 shares from its account. In a trade valued at $1,752, the SVP, Chief Financial Officer traded Editas Medicine Inc shares for $2.58 each. Upon closing the transaction, the insider’s holdings decreased to 679 shares, worth approximately $42067.5.
As published in their initiating research note from H.C. Wainwright on April 28, 2025, Editas Medicine Inc [EDIT] has been a Buy and the price target has been revised to $3. Analysts at JP Morgan downgraded the stock from ‘”a Neutral”‘ to ‘”an Underweight”‘ outlook in a report released in mid December. As of December 13, 2024, Truist has decreased its “Buy” rating to a “Hold” for EDIT. Earlier on December 13, 2024, Stifel downgraded its rating. Their new recommendation was “a Hold” for EDIT stock which previously was a “a Buy”.
Analyzing EDIT Stock Performance
On last trading session, Editas Medicine Inc [NASDAQ: EDIT] rose 1.21% to $2.5. The stock’s lowest price that day was $2.49, but it reached a high of $2.72 in the same session. During the last five days, there has been a drop of approximately -8.42%. Over the course of the year, Editas Medicine Inc shares have dropped approximately -32.61%. Shares of the company reached a 52-week high of $3.58 on 07/24/25 and a 52-week low of $0.91 on 04/07/25.
Support And Resistance Levels for Editas Medicine Inc (EDIT)
According to the 24-hour chart, there is a support level at 2.42, which, if violated, would cause prices to drop to 2.34. In the upper region, resistance lies at 2.65. The next price resistance is at 2.80. RSI (Relative Strength Index) is 44.74 on the 14-day chart, showing neutral technical sentiment.
Is Editas Medicine Inc subject to short interest?
Stocks of Editas Medicine Inc saw a sharp steep in short interest on 2025-08-15 dropping by -0.31 million shares to 8.2 million. Data from Yahoo Finance shows that the short interest on 2025-07-15 was 8.52 million shares. A decline of -3.82% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 3.37 of the overall float, the days-to-cover ratio (short ratio) decline to 3.37.
Which companies own the most shares of Editas Medicine Inc (EDIT)?
In terms of Editas Medicine Inc share price expectations, FactSet research, analysts set an average price target of 12 in the next 12 months, up nearly 385.83% from the previous closing price of $2.47. Analysts anticipate Editas Medicine Inc stock to reach 35 by 2025, with the lowest price target being 5. In spite of this, 9 analysts ranked Editas Medicine Inc stock as Buy at the end of 2025.
